Erin Harris

ARTICLES BY ERIN HARRIS

• Philadelphia As A Cell & Gene Therapy Hub

  Saul Behar, Senior Vice President, Advancement and Strategic Initiatives at University City Science Center explains why Philadelphia has a unique combination of factors in terms of the strength of its assets around academic institutions, healthcare institutions, and its rich pharma legacy

• The Greater Philadelphia Region As R&D, Manufacturing Hubs

  Cell & Gene’s Chief Editor Erin Harris asks Claire Marrazzo Greenwood, Executive Director, CEO Council for Growth & VP, Leadership Engagement at Chamber of Commerce for Greater Philadelphia about the Greater Philadelphia region as an R&D, commercialization, and manufacturing hub.

• Inside The Cell And Gene Therapy And Connected Health Workforce Analysis

  Just recently, an independent study to analyze the current workforce landscape and assess the future talent needs of the Greater Philadelphia region’s cell and gene therapy and connected health sectors has found that this workforce is expected to grow between 35 percent to 94 percent in the next 10 years using mid-range growth estimates. The growth could be as much as 54 percent to 136 percent using high-range growth estimates.

• Inside Protalix BioTherapeutics’ Phase 3 BRIDGE Study

  Protalix BioTherapeutics the significance of the positive topline results from the Phase III BRIDGE open-label switch-over study.

• BioCardia’s CEO On CardiAMP Cell Therapy Delivery

  BioCardia, a clinical-stage regenerative medicine company headquartered in San Carlos, CA, develops novel therapies to improve the lives of patients suffering from cardiovascular diseases with large unmet medical needs. BioCardia is exploring NK1R+ allogenic mesenchymal stem cells in COVID-19 induced Acute Respiratory Distress and is in the throes of its CardiAMP Cell Therapy Heart Failure Trial. To learn more about BioCardia’s on-going work, I caught up with CEO Peter Altman. Here’s what he had to say.

• Orgenesis Talks Hospital, Biotech Partnerships

  Orgenesis’ CEO, Vered Caplan discusses why the company sold its CDMO subsidiary, Masthercell, the importance of partnerships in driving down therapy costs, and more.

• An Interview With Miguel Forte, CEO, Bone Therapeutics

  In this video, Miguel Forte, CEO of Bone Therapeutics and I talk about the significance of these two studies, his work with ARM and ISCT, as well as COVID-19’s impact on the cell and gene sector.

• Adaptimmune, Cell & Gene On COVID-19’s Impact On The Cell And Gene Sector

  In this video, Michael Blackton, VP QA CMC and John Lunger Chief Patient Supply Officer at Adaptimmune talked to Cell & Gene’s Chief Editor, Erin Harris, about COVID-19’s impact on the cell and gene sector.

• ISCT On The Marketing Of Unproven COVID-19 Cell And Gene Therapies

  I caught up with Dr. Laertis Ikonomou, co-chair of the ISCT PTF and Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania and President-Elect of ISCT on the use of unproven and unethical cell and gene therapies in the age of COVID-19.

• Inside Carisma Therapeutics’ CAR-M Study

  Erin Harris talks to Michael Klichinsky, Ph.D. co-founder and VP of discovery and research at Carisma Therapeutics for more information about Carisma Therapeutics' groundbreaking CAR-M study.